<DOC>
	<DOCNO>NCT00058656</DOCNO>
	<brief_summary>Patients immune cell collect expand outside body . Patients receive infusion large number expand immune cell . There three dose level study . The goal study determine safety well potential efficacy treatment .</brief_summary>
	<brief_title>Autologous T Cell Immunotherapy Chronic Lymphocytic Leukemia ( CLL ) Patients</brief_title>
	<detailed_description>This Phase I/II single arm dose escalation study novel T cell immunotherapy chronic lymphocytic leukemia ( CLL ) . Patients receive one dose Xcellerated T Cells ( tm ) , ex vivo activate expand autologous T cell product , attempt enhance immune response anti-tumor activity . This study conduct test safety determine maximum tolerate dose ( MTD ) Xcellerated T Cells patient CLL . In addition , lymphocyte count , lymph node area , quantitative immunoglobulin assess preliminary evidence therapeutic effect . In correlative study , change phenotype T B lymphocytes evaluate flow cytometry . Changes T cell repertoire anti-tumor immune activity also assess . It expect 12 18 patient treat .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Inclusion criterion : Diagnosis CLL time past , define follow : &gt; 5 x 109 peripheral blood lymphocytes/L positive CD5 one B cell marker ( CD19 , CD20 , CD23 ) . &lt; 55 % lymphocyte identify prolymphocytes Intermediate High Risk disease define Modified 3stage system Patients Intermediate Risk ( Rai Stages I II ) must active disease , determine one follow criterion : 1 . One follow disease relate symptom . Weight loss &gt; 10 % within previous 6 month ii . Fevers great 100.5°F &gt; 2 week iii . Night sweat without evidence infection 2 . Massive ( i.e . &gt; 6 cm leave costal margin ) progressive splenomegaly 3 . Massive lymph node cluster ( i.e . &gt; 10 cm long diameter ) progressive lymphadenopathy 4 . Progressive lymphocytosis increase &gt; 50 % 2month period , anticipate double time le 12 month T cell ( CD3+ ) comprise &gt; 1.5 % &lt; 10 % peripheral white blood cell assess flow cytometry CD4+/CD8+ &gt; 0.30 , assess flow cytometry Age least 18 year ECOG performance status 0 2 Life expectancy 6 month Able comprehend provide sign informed consent Women childbearing potential must negative serum pregnancy test agree use medically accept form contraception time initial screen completion study Exclusion Criteria Evidence Richter ’ Syndrome , T cell CLL , prolymphocytic leukemia , hairycell leukemia , splenic lymphoma villous lymphocyte , large granular lymphocytosis , Sezarycell leukemia , adult Tcell leukemia/lymphoma , leukemic manifestation nonHodgkin ’ lymphoma Receipt chemotherapy , monoclonal antibody , investigational , systemic therapy treatment CLL within 2 month prior registration . Receipt glucocorticoid ( exception inhale glucocorticoid steroid use allergic rhinitis pulmonary disease ) within 2 month prior registration Receipt intravenous immunoglobulin ( IVIG ) within 1 month registration Registration , plan participate , clinical trial concurrently duration trial History malignancy CLL within five year registration , except adequately treat basal squamous cell skin cancer situ carcinoma cervix . Other exception must approve Xcyte Therapies ’ Medical Monitor prior registration . Infection require treatment antibiotic , antifungal , antiviral agent within seven day registration Liver disease hepatitis reflect serum bilirubin ALT &gt; 2.0 time upper limit normal laboratory range within 15 day registration Compromised renal function reflect serum creatinine &gt; 2 time upper limit normal laboratory range within 15 day registration History autoimmune disease unrelated CLL ( e.g. , rheumatoid arthritis , multiple sclerosis , systemic lupus erythematosis ) . Autoimmune disease relate CLL , e.g . idiopathic thrombocytopenic purpura ( ITP ) autoimmune hemolytic anemia , permit treatment steroid require two month prior registration . Hypothyroidism without evidence Grave ’ Disease Hashimoto ’ thyroiditis permit . Major organ system dysfunction include ( limited ) : New York Heart Association Class III IV ( Appendix B , page 51 ) , pulmonary disease require use inhale steroid bronchodilator , renal , hepatic , gastrointestinal , neurologic , psychiatric dysfunction would impair patient ’ ability participate trial Evidence infection HIV 1 2 , HTLV 1 2 Evidence acute active chronic Hepatitis B C infection Positive human antimouse antibody ( HAMA ) test perform central reference laboratory designate sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>T Cell Therapy</keyword>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>Xcellerate</keyword>
	<keyword>Xcellerated</keyword>
</DOC>